Aspargo Laboratories — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aspargo Laboratories, founded in 2018 and headquartered in Cambridge, USA, is a private biotech company developing a platform for oral suspension drug reformulation. Its lead asset, ASP-001 (liquid sildenafil), is commercially available in several European countries and has completed clinical trials for an FDA NDA submission. The company's strategy leverages its suspension technology to enhance bioavailability and patient adherence, with a future vision that includes a connected device platform for personalized dosing and data tracking across multiple medications.

OncologyImmunologyUrology

Technology Platform

Proprietary oral suspension technology optimizing molecular particle size, coating, and viscosity to accelerate absorption and increase bioavailability of drugs. Future platform includes a connected device with replaceable cartridges and a mobile app for data tracking.

Opportunities

The global demand for patient-friendly dosage forms, especially for populations with swallowing difficulties, presents a large and growing market.

Reformulating established drugs offers a potentially faster, lower-risk development pathway compared to novel drug discovery.

Expanding the platform into a connected device ecosystem could create a high-value digital health offering.

Risk Factors

Key risks include potential regulatory hurdles for U.S.

approval of ASP-001, intense competition in established drug markets like erectile dysfunction, and the technical challenge of successfully applying the suspension platform to a broader range of molecules.

As a private company, access to sufficient capital for expansion is also a risk.

Competitive Landscape

Aspargo competes with large pharmaceutical companies marketing original branded pills and numerous generic manufacturers. It also competes with other drug delivery and reformulation companies seeking to improve existing therapies. Its primary differentiation is its focus on optimized oral suspensions and its planned integrated device platform.

More companies in Drug Delivery & Formulation →More companies in United States →